Accretion Pharmaceuticals IPO Details
The Accretion Pharmaceuticals IPO is a book build issue with a total issue size of ₹29.75 cr, comprising of fresh issue of 2946000 equity shares. Accretion Pharmaceuticals IPO opened for subscription on May 14, 2025 and closed on May 16, 2025. Accretion Pharmaceuticals IPO is set price band at ₹96 to ₹101 per share, with a lot size of 1200 shares. Minimum investment for Retail investors was ₹242,400.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on May 19, 2025, and listed on the NSE on May 21, 2025.
Kfin Technologies Limited has been appointed as the registrar. Jawa Capital Services Private Limited are the Book Running Lead Manager for the issue.
Before investing in the Accretion Pharmaceuticals IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 96 – 101
- Lot Size
- 1200
- Issue Size
- ₹29.75 Cr
- Minimum Investment
- ₹242400 (2400 Shares)
- Listing Date
- 21 May 2025
Current GMP
₹5 (+4.95%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Accretion Pharmaceuticals Limited
Accretion Pharmaceuticals Limited, originally established as M/s Accretion Pharmaceuticals, was founded in 2012 by Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra, and Mr. Hardik Mukundbhai Prajapati with the goal of manufacturing healthcare products meeting international standards at competitive prices. The company began as a partnership firm and commenced manufacturing operations in 2014 at its facility located in Ahmedabad, Gujarat.
On October 16, 2023, the firm transitioned into a limited company under the Companies Act, 2013, and was officially incorporated as Accretion Pharmaceuticals Limited on November 29, 2023 (CIN: U21004GJ2023PLC146545).
The company is engaged in the manufacturing and marketing of a wide range of pharmaceutical products including tablets, capsules, oral liquids, external preparations (such as ointments, creams, gels, lotions, shampoos, mouthwashes, and dusting powders), and oral powders (like sachets and dry syrups). Operations include direct sales, contract manufacturing, and loan licensing for various marketers.
Accretion Pharmaceuticals operates in three business verticals:
- Domestic market sales
- Direct export sales
- Sales to merchant exporters under loan license
A significant portion of its products is exported, directly or indirectly, to markets such as Africa, South-East Asia, and Latin America. The company is ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018 certified and is managed by a professional and experienced team.
Accretion Pharmaceuticals IPO Promoters
- Mr. Mayur Popatlal Sojitra
- Mr. Harshad Nanubhai Rathod
- Mr. Vivek Ashok Kumar Patel
- Mr. Hardik Mukundbhai Prajapati
Promoters Holding
Holding Pre Issue
100.00%
Holding Post Issue
73.48%
Accretion Pharmaceuticals IPO Objective
The objects of the present issue of Equity Shares are:
a. Capital expenditure towards purchase of new equipment/machineries, etc.
b. Capital expenditure towards upgradation of existing manufacturing facility;
c. Repayment/prepayment of certain borrowings availed by our Company;
d. Funding working capital requirements; and
e. General Corporate Purpose
Address / Contact Info
Accretion Pharmaceuticals Limited
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals,
Vasna Chacharvadi, Ahmedabad,
Sanand, Gujarat,-382213
Phone: +91-97148 82929
Email: compliance@accretionpharma.com
Website: https://accretionpharma.com/
IPO Snapshot
Book Running Lead Managers
- Jawa Capital Services Private Limited
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Accretion Pharmaceuticals IPO is a Book-building IPO with a total issue size of ₹29.75 crore. The Accretion Pharmaceuticals IPO price band is ₹96 to 101 per share. The Accretion Pharmaceuticals IPO subscription opens on Wed, May 14, 2025, and closes on Fri, May 16, 2025. The Accretion Pharmaceuticals IPO will be listed on the NSE. Kfin Technologies Limited is the registrar for the Accretion Pharmaceuticals IPO.
The Accretion Pharmaceuticals IPO opens on Wed, May 14, 2025 and closes on Fri, May 16, 2025
Accretion Pharmaceuticals IPO Price Band is ₹96 to 101 per share.
Accretion Pharmaceuticals IPO lot size is 1200 shares, Retail investors need a minimum investment of ₹242400 based on the upper price band
The minimum investment for Accretion Pharmaceuticals IPO is ₹242400, based on one lot of 1200 shares at the upper price band of ₹101 per share.
Investors can apply for the Accretion Pharmaceuticals IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, May 16, 2025. The application amount remains blocked until the Accretion Pharmaceuticals IPO allotment is finalized.
Accretion Pharmaceuticals IPO issue size is ₹29.75 crores.
Accretion Pharmaceuticals IPO allotment date is Wed, Jul 1, 2026.
The registrar for Accretion Pharmaceuticals IPO is Kfin Technologies Limited. Investors can go to Kfin Technologies Limited website to check Accretion Pharmaceuticals IPO allotment status, refund processing, and other IPO-related information.
The Accretion Pharmaceuticals IPO GMP (Grey Market Premium) is ₹5 as of Fri, May 16, 2025. Based on the upper price band of ₹101 per share, the estimated Accretion Pharmaceuticals IPO listing price is ₹106, indicating a potential listing gain of approximately 0% over the issue price.